Compared with placebo , teriflunomide significantly reduced the risk of relapse defining clinically definite multiple sclerosis at the @ mg dose ( hazard ratio -LSB- HR -RSB- @ -LSB- @ % CI @-@ -RSB- ; p = @ ) and at the @ mg dose ( @ -LSB- @-@ -RSB- ; p = @ ) .